What is Zacks Research’s Estimate for PBH Q2 Earnings?

Posted by Geri Gentry on Aug 27th, 2026

Prestige Consumer Healthcare Inc. (NYSE:PBH – Free Report) – Equities researchers at Zacks Research issued their Q2 2027 EPS estimates for Prestige Consumer Healthcare in a report released on Tuesday, August 25th. Zacks Research analyst Team anticipates that the company will post earnings of $1.06 per share for the quarter. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.56 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s Q3 2027 earnings at $1.22 EPS, Q4 2027 earnings at $1.30 EPS, FY2027 earnings at $4.55 EPS, Q1 2028 earnings at $1.14 EPS, Q2 2028 earnings at $1.19 EPS, Q3 2028 earnings at $1.38 EPS, Q4 2028 earnings at $1.35 EPS, FY2028 earnings at $5.06 EPS, Q1 2029 earnings at $1.20 EPS and FY2029 earnings at $5.25 EPS.

Several other analysts have also recently commented on the company. Weiss Ratings cut Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, June 25th. Oppenheimer downgraded shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Finally, Canaccord Genuity Group decreased their price objective on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Two analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $70.75.

Get Our Latest Stock Report on Prestige Consumer Healthcare

Prestige Consumer Healthcare Trading Up 1.3%

Shares of PBH opened at $52.11 on Thursday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.99 and a current ratio of 3.23. The company has a market cap of $2.47 billion, a price-to-earnings ratio of 14.60, a PEG ratio of 1.61 and a beta of 0.34. The stock has a fifty day moving average price of $50.03 and a two-hundred day moving average price of $54.74. Prestige Consumer Healthcare has a 52-week low of $42.62 and a 52-week high of $71.07.

Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.89 by $0.09. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The business had revenue of $265.71 million for the quarter, compared to analyst estimates of $253.02 million. During the same period in the prior year, the company earned $0.90 EPS. Prestige Consumer Healthcare’s revenue for the quarter was up 6.5% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Lido Advisors LLC boosted its stake in shares of Prestige Consumer Healthcare by 5.4% during the fourth quarter. Lido Advisors LLC now owns 3,778 shares of the company’s stock valued at $235,000 after purchasing an additional 192 shares in the last quarter. Cerity Partners LLC increased its stake in shares of Prestige Consumer Healthcare by 5.9% in the second quarter. Cerity Partners LLC now owns 3,884 shares of the company’s stock valued at $310,000 after buying an additional 218 shares during the period. UMB Bank n.a. increased its stake in shares of Prestige Consumer Healthcare by 110.1% in the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after buying an additional 219 shares during the period. Versant Capital Management Inc raised its holdings in Prestige Consumer Healthcare by 47.9% in the 2nd quarter. Versant Capital Management Inc now owns 726 shares of the company’s stock valued at $34,000 after buying an additional 235 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its position in Prestige Consumer Healthcare by 69.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock worth $35,000 after buying an additional 236 shares during the period. 99.95% of the stock is currently owned by institutional investors.

Key Headlines Impacting Prestige Consumer Healthcare

Here are the key news stories impacting Prestige Consumer Healthcare this week:

Positive Sentiment: Zacks projects earnings per share of $4.55 for FY2027, increasing to $5.06 in FY2028 and $5.25 in FY2029. That outlook suggests continued earnings growth for PBH, which could support investor interest over the longer term.
Neutral Sentiment: The estimates include quarterly EPS forecasts of $1.06 for Q2 FY2027, $1.22 for Q3, and $1.30 for Q4, followed by $1.14, $1.19, $1.38, and $1.35 for FY2028’s quarters. These forecasts indicate relatively consistent profitability rather than a near-term earnings acceleration.
Neutral Sentiment: Zacks’ FY2027 forecast of $4.55 is essentially in line with the current consensus estimate of $4.56, limiting the immediate upside from estimate revisions. The firm’s unchanged “Hold” rating also signals that valuation and growth prospects are viewed as fairly balanced.

Prestige Consumer Healthcare Company Profile

(Get Free Report)

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).